Development and Validation of an LC-MS/MS Method for the Quantitation of JNJ-64619178 (JNJ) in Mouse Plasma: Characterization of In Vitro and In Vivo Pharmacokinetic Properties
Molecules · 23.04.2026 · 31 (9) · 1396
DOI: 10.3390/molecules31091396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 23.04.2026. Verfasst von Nusrat Ahmed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE 68198, USA. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Team Jack Foundation, UNMC CHRI-PCRG, Team Jack Foundation Power 5.
Abstract (Originalsprache)
Overexpression of protein arginine methyltransferase 5 (PRMT5) is pivotal in MYC-driven primary medulloblastoma tumors, suggesting PRMT5 as a potential therapeutic target. JNJ, a potent PRMT5 inhibitor currently in clinical trials, notably for non-Hodgkin lymphoma and lung cancer, was evaluated in this study. We report a validated LC–MS/MS bioanalytical method for quantifying JNJ in plasma and tissue matrices. The method demonstrated acceptable sensitivity, selectivity, and robustness in accordance with regulatory guidelines. The assay was linear over the range 0.2–500 ng mL−1 (r2 = 0.99), with plasma recovery exceeding 84% using only 100 µL of sample. Precision (%RSD < 15%) and accuracy (~91–108%) were within acceptable limits. JNJ showed >94% plasma protein binding and moderate Caco-2 permeability (3.4 ± 0.4 × 10−6 cm s−1). Hepatic intrinsic clearance was higher in mouse liver microsomes than in human (41 ± 19 vs. 7 ± 0.6 mL min−1 kg−1). Following oral dosing in mice (10 mg kg−1), Tmax was 30 min with a Cmax of 2781 ± 1033 ng mL−1. Oral bioavailability was low (15%). The validated method was successfully applied to in vitro and in vivo studies and will guide dosing in animal models of medulloblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Laboratory, Department of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Division of Hematology/Oncology, Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198, USA.
ORCID-Profile: Nusrat Ahmed, Pratiksha Kshirsagar, Ling Ding, Daryl J Murry, Nagendra K Chaturvedi
Förderung
- Team Jack Foundation
- UNMC CHRI-PCRG
- Team Jack Foundation Power 5
- UNMC Child Health Research Institute-Pediatric Cancer Research Group
Zitieren
APA
Ahmed, N., Kshirsagar, P., Ding, L., Murry, D. J., Chaturvedi, N. K., & Chhonker, Y. S. (2026). Development and Validation of an LC-MS/MS Method for the Quantitation of JNJ-64619178 (JNJ) in Mouse Plasma: Characterization of In Vitro and In Vivo Pharmacokinetic Properties. Molecules, 31(9), 1396. https://doi.org/10.3390/molecules31091396
Vancouver
Ahmed N, Kshirsagar P, Ding L, Murry DJ, Chaturvedi NK, Chhonker YS. Development and Validation of an LC-MS/MS Method for the Quantitation of JNJ-64619178 (JNJ) in Mouse Plasma: Characterization of In Vitro and In Vivo Pharmacokinetic Properties. Molecules. 2026;31(9):1396. doi:10.3390/molecules31091396
BibTeX
@article{Ahmed2026,
author = {Ahmed, Nusrat and Kshirsagar, Pratiksha and Ding, Ling and Murry, Daryl J and Chaturvedi, Nagendra K and Chhonker, Yashpal S},
title = {Development and Validation of an LC-MS/MS Method for the Quantitation of JNJ-64619178 (JNJ) in Mouse Plasma: Characterization of In Vitro and In Vivo Pharmacokinetic Properties},
journal = {Molecules},
year = {2026},
volume = {31},
number = {9},
pages = {1396},
doi = {10.3390/molecules31091396}
}
EUVIMED